Stock comparison
Gilead Sciences
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GILD
Gilead Sciences
Market cap
$166.82B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GILD | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 60C | 69B | MTD |
| Benjamin Graham | 73B | 65B | GILD |
| Philip Fisher | 61C | 63C | MTD |
| Peter Lynch | 55C | 66B | MTD |
| Joel Greenblatt | 47D | 68B | MTD |
| Charlie Munger | 74C | 74B | Tie |
| Terry Smith | 71B | 70B | GILD |
Side-by-side metrics
| Metric | GILD | MTD |
|---|---|---|
| Market cap | $166.82B | $22.29B |
| P/E (TTM) | 17.5x | 25.3x |
| EV/EBIT | 15.0x | 21.6x |
| ROIC (TTM) | 20.31% | 36.09% |
| Gross margin | 79.35% | 57.79% |
| Net margin | 30.99% | 21.4% |
| Revenue CAGR 5y | 1.9% | 2.01% |
| EPS CAGR 5y | 8.37% | 6.12% |
| Debt / Equity | 0.9x | - |
| Dividend yield | 2.46% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GILD leads on
- Dividend yield2.46%vs 0.0%+100%
- Market cap$166.82Bvs $22.29B+87%
- Net margin30.99%vs 21.4%+31%
- P/E (TTM)17.5xvs 25.3x+31%
MTD leads on
- Debt / Equity-vs 0.9x+102%
- ROIC (TTM)36.09%vs 20.31%+44%
- Revenue CAGR 5y2.01%vs 1.9%+6%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.